Circulating Endothelial-Derived Activated Microparticle: A Useful Biomarker for Predicting One-Year Mortality in Patients with Advanced Non-Small Cell Lung Cancer

Table 2

Flow cytometric quantification of circulating MPs levels among the 107 study patients.

Variables	One-year survivors; (𝑛=56)	One-year nonsurvivors; (𝑛=51)	𝑃 value
CD31^+CD42b^−AN-V^+ (counts/mL)*	9604.47 ± 10879.55	8979.27 ± 8496.78	0.743
CD31^+CD42b^−AN-V^− (counts/mL)*	942.33 ± 1556.86	2473.18 ± 3827.60	0.006
CD31^+CD42b^+AN-V^+ (counts/mL)*	30435.52 ± 29380.62	39718.43 ± 32105.38	0.118
CD31^+CD42b^+AN-V^− (counts/mL)*	92391.74 ± 206545.58	48540.96 ± 100731.50	0.171
CEA^†	45.59 ± 119.28	130.11 ± 456.11	0.177

∗CD31⁺CD42b⁻AN-V⁺ = endothelial-derived apoptotic microparticles; CD31⁺CD42b⁻AN-V⁻ = endothelial-derived activated microparticles; CD31⁺CD42b⁺AN-V⁺ = platelet-derived apoptotic microparticles; CD31⁺CD42b⁺AN-V⁻ = platelet-derived activated microparticles.
^†CEA: carcinoembryonic antigen.